md-medicaldata

Authors

 

Vladan Lukić¹, Aleksandra Kovačević², Nemanja Rančić², Viktorija Dragojević-Simić<sup>2

1</sup>Nacionalni centar za kontrolu trovanja, Medicinski fakultet Vojnomedicinska akademija, Univerzitet odbrane, Beograd, Srbija / National Poison Control Center, Medical Faculty of the Military Medical Academy, University of Defence, Belgrade, Republic of Serbia
²Centar za kliničku farmakologiju, Medicinski fakultet Vojnomedicinska akademija, Univerzitet odbrane, Beograd, Srbija / Center for Clinical Pharmacology, Medical Faculty of the Military Medical Academy, University of Defence, Belgrade, Republic of Serbia

 

The paper was received on 06.04.2017. / Accepted on 10.04.2017

 

Correspondence to

Naučni saradnik dr sc. med. Nemanja Rančić;
Centar za kliničku farmakologiju,
Medicinski fakultet Vojnomedicinska akademija,
Univerzitet odbrane,
Beograd, Srbija; Crnotravska 17, 11002 Beograd, Srbija;
Tel.: +381638524443;
e-mail: : nece84@hotmail.com

 

 

Abstract

 

Background: Maprotiline is a tetracyclic antidepressant, therapeutically used for depressive disorders particularly if anxiety is associated with depression. It inhibits reuptake of biogenic amines, especially noradrenaline. Objective: This case report is related to gynecomastia as a probable maprotiline-related adverse effect, with almost no report in the available literature. Case report: A 72 years old man has been referred to clinical pharmacologist due to suspicion that pain and discomfort in both breasts, as well as gynecomastia diagnosed by physical and ultrasound examination are related with some of the prescribed drugs. After recommended maprotiline discontinuation, symptoms and signs of gynecomastia have been withdrawn. Conclusion: Gynecomastia can be manifested as a very rare adverse effect of maprotiline, even after irregular application of subtherapeutic doses of drug. This disorder is reversible and subsides soon after withdrawal of the drug.

 

 

 

Key words:

maprotiline, adverse effects, gynecomastia

 

 

Sažetak

 

Uvod: Maprotilin spada u grupu tetracikličnih antidepresiva, koji se danas prvenstveno koristi za lečenje bolesnika kod kojih je depresija udružena sa anksioznošću. Svoje dejstvo ostvaruje inhibicijom preuzimanja noradrenalina, dok je preuzimanje serotonina i dopamina slabije izraženo. Cilj: U radu je prikazan slučaj pojave ginekomastije kao verovatne neželjene reakcije na maprotilin, o čemu gotovo da nema podataka u dostupnoj literaturi. Prikaz slučaja: Muškarac, star 72 godine, se javio na pregled kod kliničkog farmakologa zbog sumnje da su pojava bolova i osećaj nelagodnosti u obe dojke, kao i fizikalnim i ultrazvučnim pregledom nađena ginekomastija povezani sa uzimanjem nekog od propisanih lekova. Nakon predloženog prestanka uzimanja maprotilina došlo je do povlačenja simptoma i znakova ginekomastije. Zaključak: Ginekomastija se može javiti kao veoma retka neželjena reakcija na anidepresiv maprotilin, čak i kod neredovne primene subterapijskih doza leka. Ova pojava je reverzibilna i povlači se vrlo brzo nakon obustave leka.

 

 

Ključne reči:

maprotilin, neželjena reakcija na lek, ginekomastija

 

 

References

 

1. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000; 58(1):19-36
2. Peng WH, Lo KL, Lee YH, Hung TH, Lin YC. Berberine produces antidepressant-like effects in the forced swim test and in the tail suspension test in mice. Life Sci. 2007; 81(11):933-8.
3. Matthys A, Haegeman G, Van Craenenbroeck K, Vanhoenacker P. Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives. Mol Neurobiol. 2011; 43(3):228-53.
4. Delini-Stula A, Mikkelsen H, Angst J. Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies; J Affect Disord. 1995; 35(1-2):21-30.
5. Derkacz M, Chmiel-Perzyńska I, Nowakowski A. Gynecomastia - a difficult diagnostic problem. Endokrynol Pol. 2011; 62(2):190-202.
6. Nuttall FQ, Warrier RS, Gannon MC. Gynecomastia and drugs: a critical evaluation of the literature. Eur J Clin Pharmacol. 2015; 71(5):569-78.
7. Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf. 2012; 11(5):779-95.
8. Аgеnciја zа lеkоvе i mеdicinskа srеdstvа. Sažetak karakteristika leka Maprotilin film tablete 50 mg. ALIMS, decembar 2013. (Preuzeto 31.03.2017. sa:  http://www.alims.gov.rs/ciril/files/lekovi/smpc/515-01-05658-13-002.pdf) 
9. The use of the WHO-UMC system for standardised case causality assessment. The Uppsala Monitoring Centre. (Preuzeto 31.03.2017. sa: https://www.who-umc.org/media/2768/standardised-case-causality-assessment.pdf)
10. Lemaine V, Cayci C, Simmons P, Petty P. Gynecomastia in Adolescent Males. Semin Plast Surg. 2013; 27(1): 56-61.
11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. (Preuzeto 31.03.2017. sa: http://www.alims.gov.rs/ciril/files/lekovi/smpc/515-01-05658-13-002.pdf)
12. Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics-a review. Hum Psychopharmacol. 2010; 25(4):281-97.
13. Аgеnciја zа lеkоvе i mеdicinskа srеdstvа. Sažetak karakteristika leka Citalex® film tableta 10 mg. ALIMS, maj 2012. (Preuzeto 31.03.2017. sa: http://www.alims.gov.rs/ciril/files/lekovi/smpc/515-01-9056-11-001.pdf)
14. Aronson JK. Meyler's Side Effects of Psychiatric Drugs. Selective Serotonin Re-Uptake Inhibitors. Amsterdam: Elsevier; 2009: 37-76.

UDK: 615.214.23.065
618.19-055.1
COBISS.SR-ID 239049740

PDF Lukić V. et al. MD-Medical Data 2017;9(2): 127-131